- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00337012
The Effect of Duloxetine on Interoceptive Awareness
November 28, 2008 updated by: University Hospital, Bonn
The Effect of Duloxetine on Interoceptive Awareness, Thermal Heat Pain Perception, and Bodily Symptoms in Major Depressive: a Pilot Study With fMRI.
This study focuses on possible mechanism mediating duloxetine effects on painful physical symptoms in patients suffering from MDD.
Our hypothesis is based on the assump¬tion of dual impairment of the somatosensory system in these patients.
Hypalgesia to phasic experimental pain may be due to diminished spinal and brainstem transmission.
Hyperalgesia may be at¬tributed to increased interoceptive perception (somatic complaints, especially those consist¬ing in pain) due to sensitisation or lack of inhibition of the interceptive perception.
These ef¬fects seem to be mediated by specific brain regions (e.g. the right insula).
The investigators intent to test if duloxetine effects on these somatic complaints, especially pain complaints are due to a nor¬malization of these interceptive alterations which have been reported to be associated with depressive symptoms.
The investigators hypothesize that treatment with duloxetine will normalize "patho¬logical" activation patterns (as assessed by fMRI) associated with increased interoceptive perception.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
36
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Christian G Schuetz, MD MPH
- Phone Number: +49 228 287 9664
- Email: christian.schütz@ukb.uni-bonn.de
Study Locations
-
-
NRW
-
Bonn, NRW, Germany, 53105
- Recruiting
- University Clinic Bonn
-
Contact:
- Christian G Schütz
- Phone Number: +49 228 2879664
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female (female are enrolled only under the condition of proof of using a safe and medially accepted contraceptive. According to the "Note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals" (CPMP/ICH/286/95, modification) contraceptives with a pearl-index<1% are considered safe and effective. Among these only hormonal contraceptives, micro-pill and tubal ligantions will be accepted in this study)
- Between the ages of 21 and 65 years; and
- A diagnosis of major depression (HDRS>=15) and
- A minimum of 25 mm on a VAS measure of painful symptoms (ranging from 0-100 mm), but no need for regular pain medication and HAMD-17 item 13 minimum rated as 1,
- Medically and neurologically healthy on the basis of history, physical examination, EKG, screening laboratories (CBC w/ differential, TSH, Free-T4, ASAT, ALAT, GGT, BUN, creatinine, calcium, phosphorous, magnesium, total protein, albumin, electrolytes) and
- Absence of substance abuse on the basis of history and urine toxicology at screening.
Exclusion Criteria:
- DSM-IV psychiatric and substance abuse diagnosis (excluding nicotine dependence) by history or psychiatric evaluation that includes a structured diagnostic interview for non-patient populations (SCID-NP)
- Current suicide risk sufficient to preclude treatment on an outpatient base: Higher than "2" on the "suicide" item of HAMD-17, or history of suicide attempt(s) in the past 12 months, or who, in the investigator's judgment, poses a current suicidal or homicidal risk.
- Clinical indications of organic brain disease, dementia, or cognitive impairment.
- History of substance dependence other than nicotine and consumption within the last year
Any medical condition that would preclude the use of duloxetine treatment as
- A known hypersensitivity to duloxetine or any of the inactive ingredients.
- Intake of monoamine oxidase inhibitors (MAOIs) or suffering from uncontrolled narrow-angle glaucoma.
- Signs of any hepatic insufficiency
- Intake of inhibitors of CYP1A2 (as fluvoxamine, ciprofloxacin, enoxacin)
- End-stage renal disease (requiring dialysis) or severe renal impairment (estimated creatinine clearance [CrCl] <30 mL/min)
Subnormal intellectual potential as assessed by the WST-IQ [Metzler. und Schmidt, 1992]
- Healthy controls will meet exclusion and inclusion criteria, but will have no current or prior diagnosis of major depression.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Wolfgang Maier, Prof. Dr., University of Bonn, Department of Psychiatry
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2007
Study Registration Dates
First Submitted
June 13, 2006
First Submitted That Met QC Criteria
June 13, 2006
First Posted (Estimate)
June 15, 2006
Study Record Updates
Last Update Posted (Estimate)
December 1, 2008
Last Update Submitted That Met QC Criteria
November 28, 2008
Last Verified
November 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006-001079-39
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom